Wootrader.com is moving to https://financeboards.com - sign up for a free account.

Pharma


If you doubt the value of low-priced stocks, keep in mind that Apple Inc. (NASDAQ:AAPLC), Bank of America Corp. (NYSE:BACD) and Ford Motor Co. (NYSE:FD) – to name just a few – once traded in the single digits. Discovering and cashing in on an inexpensive stock with upside potential can be exhilarating.

Of course low-priced stocks come with the same risks as any other stock. So, there’s always that.

That said, here are 5 Woo Trader pharma favorites, all currently priced at less than 5 bucks, along with some stats and analyst opinions on stocks that some believe could be a good buy moving forward.

Related: What Is Sector Rotation?

AcelRX Pharmaceuticals Inc. (NASDAQ:ACRXA)

According to BibeyPost, of analysts covering AcelRx Pharmaceuticals, 4 rate it a “Buy,” 0 “Sell,” and 2 “Hold.” Woo Trader’s Performance Weighted Rating is “Outperform” and Zacks Rating is also “Buy.” The company’s 50 day moving average is $3.51, market cap is $165.34 million.

AcelRx Pharmaceuticals, Inc. is a development-stage specialty pharmaceutical company. Primary focus is on the development of therapies for treatment of acute pain. Zalviso, the company’s prime candidate, is a sublingual tablet designed to mitigate pain in hospitalized adults.

XOMA Corp. (NASDAQ:XOMAC)

Zergwatch likes XOMA Corp. in the biotech space, noting a 5% positive bump in recent trading. Average volume is 1.56 million shares and the stock currently sits 28% above its 52-week low.

XOMA is involved in the creation and manufacture of therapeutic antibodies to treat autoimmune, infectious, inflammatory and oncological diseases. The company's flagship product is an antibody designed to treat inflammation brought on by a number of diseases.

Woo Trader rates XOMA “Perform” with a Top Rating of “Buy.” Zacks has a “Hold” rating on XOMA and notes that analyst sentiment has moved higher in recent weeks.

Galectin Therapeutics Inc. (NASDAQ:GALTA)

Galectin received a boost April 11 when Zacks Investment Research noted the 3 brokers that cover the stock rated it a “Strong Buy.” Zacks price target for GALT is $10, while Woo Trader pegs the PT at $8.

Massachusetts-based Galectin is a drug development company involved in creating new therapies for fibrotic disease and cancer. Using carbohydrate technology, GALT’s therapies target galectin proteins.

With Woo Trader rating the stock “Outperform,” Zacks calling it a “Strong Buy” and a Woo Trader Top Rating of “Buy,” GALT has a lot going for it. And the stock, which closed Thursday up 4% at $1.54, fits well within the “under $5” theme.

Rigel Pharmaceuticals Inc. (NASDAQ:RIGLB)

When Rigel reports Q1 earnings, expected May 3, analysts anticipate EPS of $-0.23 on revenue of $4 million. Importantly, the company’s average per share beat rate has been 15.9%.

Rigel Pharmaceuticals is a clinical-stage drug development company that specializes in small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. The company’s goal is to file one new investigative new drug application each year.

Woo Trader rates RIGL “Outperform” and Zacks calls it a “Strong Buy” with a PT of $10 on this stock that last closed at $2.49, up less than 1% on the day, Thursday.

Related: Analysts On Oil Stocks You Should Consider Buying

Geron Corp. (NASDAQ:GERNB)

Rounding out this list of low-priced pharma, Geron has been on the radar of analysts for a while now. As major companies take a beating from drug pricing scandals and other negative news, Geron has been working with Johnson & Johnson’s JNJ Janssen Biotech in the oncology space.

Geron’s specialties include cellular aging and cancer, pluripotent stem cells as a potential source of replacement cells and tissues and nuclear transfer as a potential mechanism for generating genetically matched cells and tissues.

Holding another “Outperform” rating from Woo Trader and a “Buy” from Zacks, along with a Zacks PT of $7.50, Geron, $3.26 stock (up 1.2% Thursday) could be an attractive option in the low-priced pharma space.



Get Started For Free